People’s Perception on COVID-19 Vaccine and Its Accessibility

Message from the Guest Editors

A strategic vision for pandemic control across different countries must include all the potential gains from population-level immunity—not only health improvements and the prevention of mortality and morbidity but also strong psychosocial and economic protection from further catastrophic consequences. Vaccine hesitancy is a reality but needs to be addressed and minimized, and there are several factors associated with it globally. However, to overcome this critical challenge during the management of the pandemic, it is the responsibility of not only public health practitioners but also the global science community, influential and popular individuals, and political leaders to raise public awareness through health-promotion campaigns.

Emerging scientific evidence from population-level vaccinations will accelerate the global promotion of vaccination.

In this Special Issue, we are calling for contributors from every corner of the world to disseminate research activities related to COVID-19 vaccine hesitancy and vaccine-shortage issues.
Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: — free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Immunology) / CiteScore - Q1 (Pharmacology (medical))